Prezista oral suspension launched

Prezista (darunavir) is now available as a 100mg/ml oral suspension.

Prezista (darunavir) is licensed for use in all adult patients as well as in antiretroviral treatment-experienced paediatric patients aged 3 years and over who weigh at least 15kg
Prezista (darunavir) is licensed for use in all adult patients as well as in antiretroviral treatment-experienced paediatric patients aged 3 years and over who weigh at least 15kg

Prezista (darunavir) is indicated in combination with low dose ritonavir and together with other antiretrovirals for the treatment of HIV-1 infection.

It may be used to administer doses to paediatric patients or in adult patients unable to swallow tablets.

View Prezista drug record

Further information: Janssen-Cilag Ltd

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more